Coronary Artery Disease
Conditions
Interventions
Atorvastatin (10mg/day). Study preriod is Dec. 2008-Sep. 2010.
Rosvastatin (2.5mg/day) Study preriod is Dec. 2008-Sep. 2010.
Sponsors
Division of cardiology, Department of Internal Medicine, Memorial Heart Center, Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1) Coroanry artery disease with hyperlipidemia, 2) Acceptable for prescription of Atorvastatin and rosvastatin 3) ACC/AHA guideline diagnositic criteria (J Am Coll Cardiol. 2002;40:1366-74) 4) Patients after coronary intervention 5) Acceptable follow up in our center 6) Age: over 20 years old 7) Sex: undetermined
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1) stand by scheduled CABG during study period 2) valvelar heart disease 3) chronic lung disease, cor plumonale 4) poor prognosis disease (malignant tumor etc.) within 5 years 5) bilateral renal artery stenosis, one-side kidney and renal artery stenosis, high potassium (K 5.0mEq/L), renal insufficiency (creatine 3.0mg/dL), liver dysfunction (AST>100 U/L, ALT>100U/L), anemia (Hb <6.0mg/dL) 6) in pregnancy (including suspicious state) , the lactation period 7) drug allergy for HMG-CoA reductase inhibitor 8) contraindication of HMG-CoA reductase inhibitor 9) could not obtained written informed consent 10) unfavorable patient for this study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1:plaque evaluation using IVUS 2:EPC function, immunological response of monocyto 3:all cause death, all cause cardiovascular event 4:repeat revascularization | — |
Countries
Japan
Contacts
Public ContactTomonori Itoh
Iwate Medical University Division of cardiology, Department of Internal Medicine, Memorial Heart Center
Outcome results
None listed